Blog
RSS FeedPosted by Michael Wonder on 24 Oct 2018
MS and cholesterol drugs picked for new UK rapid uptake push
24 October 2018 - Accelerated Access Collaborative aims to break down barriers to faster uptake ...
Posted by Michael Wonder on 24 Oct 2018
Further update on proposal to fund glecaprevir with pibrentasvir (Maviret) for hepatitis C
24 October 2018 - This is a further update on the proposal to fund glecaprevir with pibrentasvir (Maviret) for hepatitis ...
Posted by Michael Wonder on 23 Oct 2018
$80 million investment in eye medication
24 October 2018 - The Australian Government will invest $80 million in eye medications through the Pharmaceutical Benefits Scheme, helping improve ...
Posted by Michael Wonder on 23 Oct 2018
Biosimilar adalimumab: a landmark for NHS medicines optimisation
23 October 2018 - The NHS’s bid to improve patient outcomes and save money by switching costly biological drugs for ...
Posted by Michael Wonder on 23 Oct 2018
$6.8 billion ‘high claim’ health cost sparks private insurer outcry
23 October 2018 - Australia’s private health funds paid $6.82 billion in “high claims” in one year, prompting renewed concerns ...
Posted by Michael Wonder on 23 Oct 2018
Eye disease drugs added to the PBS to benefit thousands of Australians
24 October 2018 - Thousands of Australians will have their vision saved or prolonged through increased access to eye medications. ...
Posted by Michael Wonder on 23 Oct 2018
NZ patients with ALK positive non-small-cell lung cancer score a minor win
23 October 2018 - PTAC has recommended that alectinib hydrochloride be funded for the first-line treatment of ALK positive, locally ...
Posted by Michael Wonder on 22 Oct 2018
Hatred of big pharma won’t get us better drug prices
22 October 2018 - The story of how Remicade became Canada’s most lucrative drug with sales topping $1.1-billion – told ...
Posted by Michael Wonder on 22 Oct 2018
How pharma companies try to use funding to sway patient advocate groups
21 October 2018 - Like many patient advocacy groups, the Canadian Spondylitis Association – which is focused on arthritis in the ...
Posted by Michael Wonder on 22 Oct 2018
Lung cancer survivor wants PHARMAC to fund drugs she received in trial
22 October 2018 - Lung cancer patient Marjolein Baas takes the drug ceritinib, one of six lung cancer treatment drugs the ...
Posted by Michael Wonder on 22 Oct 2018
Pharmaceutical pricing conundrum: time to get rid of it?
21 October 2018 - A basic concept of economics is that a price stems from the intersection between supply and demand ...
Posted by Michael Wonder on 20 Oct 2018
Is the EUnetHTA HTA core model fit for purpose? Evaluation from an industry perspective
18 October 2018 - The HTA Core Model was developed to improve the transferability of health technology assessment between settings. ...
Posted by Michael Wonder on 20 Oct 2018
Cost, context, and decisions in health economics and health technology assessment
18 October 2018 - This study is an attempt to demystify and clarify the idea of cost in health economics ...
Posted by Michael Wonder on 20 Oct 2018
Some European countries decide to cover cancer drugs much faster than others
19 October 2018 - Some European countries take more than twice as long as others to decide whether to provide ...
Posted by Michael Wonder on 19 Oct 2018
Competition watchdog’s appeal over Pfizer ruling dismissed
19 October 2018 - The High Court has dismissed the ACCC’s application to appeal a decision on whether Pfizer’s local ...